Geneva, Switzerland and Boston, MA – October 9, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage…
Category: Press release
The press releases from ObsEva
ObsEva SA to Participate in Cantor Global Healthcare Conference October 2-4, 2019
Geneva, Switzerland and Boston, MA – September 27, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical…
ObsEva announces new composition of its Executive Committee
Geneva, Switzerland and Boston, MA – September 11, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage…
ObsEva Reports New Clinical Evidence of Nolasiban Mechanism of Action, Supporting Its Potential to Increase Live Birth Rate Following Embryo Transfer in IVF
Results show decreased uterine contractions, increased endometrial blood flow and gene expression relevant for uterine receptivity to implantation 4Q:19 Read-out…
ObsEva SA to Participate in Upcoming Investor Conferences
Geneva, Switzerland and Boston, MA – August 30, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical…
ObsEva SA to Participate in Wedbush PacGrow Healthcare Conference August 13- 14, 2019
Geneva, Switzerland and Boston, MA – August 9, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical…
ObsEva SA Announces $75 Million Credit Facility with Oxford Finance LLC
Geneva, Switzerland and Boston, MA – August 7, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage…
ObsEva Reports Second Quarter 2019 Financial Results
Multiple Major Milestones Expected This Year Q4:19 Phase 3 data for IMPLANT 4 trial of nolasiban Nolasiban MAA…
ObsEva SA to Hold Second Quarter 2019 Financial Results and Business Update Call on August 7, 2019
Geneva, Switzerland and Boston, MA – August 5, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage…
ObsEva SA Reports Positive Feedback from Independent Data Monitoring Committee for PROLONG Part B with OBE022
Geneva, Switzerland and Boston, MA – July 26, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical…